Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)

Table 3 Demographic and clinical characteristics and their association with sufficient overall symptom relief after 4 weeks of treatment on multivariate logistic regression analysis

Variable	OR (95% CI)
Drug
Omeprazole	1.00
Teprenone	0.22 (0.11–0.42)
Mosapride	0.28 (0.16–0.48)
Famotidine	0.30 (0.17–0.51)
Sex
Male	1.00
Female	0.80 (0.49–1.32)
Age, y
< 60	1.00
≥ 60	1.0 (0.98–1.01)
BMI, *kg/m* ²
< 25	1.00
≥ 25	0.98 (0.91–1.06)
Smoking status
Non-smoker	1.00
Smoker	1.01 (0.69–1.48)
Alcohol intake
Non-drinker	1.00
Drinker	0.94 (0.69–1.28)
Number of symptoms at baseline
< 5	1.00
≥ 5	0.48 (0.29–0.81)
Symptom severity
Less than severe	1.00
Severe	0.65 (0.39–1.08)
Symptom type
GERD-type*	1.23 (0.78–2.0)
FD-type*	1.67 (1.01–2.8)
Others*	0.85 (0.55–1.30)

*Compared with patients who did not have this symptom type. OR, odds ratio; CI, confidence interval; BMI, body mass index; FD, functional dyspepsia; GERD, gastroesophageal reflux disease.

ISSN: 1471-230X